Short Interest in CureVac N.V. (NASDAQ:CVAC) Decreases By 30.0%
CureVac N.V. (NASDAQ:CVAC) experienced a significant decrease in short interest, dropping 30.0% in July to 741,700 shares. This represents 0.8% of the company's shares short sold, with a short-interest ratio of 0.6 days based on an average trading volume of 1,210,000 shares. The stock opened at $5.46, with a market cap of $1.22 billion and a P/E ratio of 5.69. Analysts have mixed ratings, with a consensus rating of "Hold" and a price target of $6.83. Institutional investors own 17.26% of the stock.
CureVac N.V. (NASDAQ:CVAC - Get Free Report) was the target of a large drop in short interest in July. As of July 31st, there was short interest totaling 741,700 shares, adropof30.0% from the July 15th total of 1,060,000 shares. Approximately0.8% of the shares of the stock are short sold. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately0.8% of the shares of the stock are short sold.
CureVac Price Performance
- 2 Small-Cap Stocks Set to Shine in a Bull Market
NASDAQ CVAC opened at $5.46 on Wednesday. The business has a 50 day simple moving average of $5.42 and a 200 day simple moving average of $4.11. CureVac has a 52-week low of $2.37 and a 52-week high of $5.72. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.64 and a current ratio of 6.17. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 5.69 and a beta of 2.53.
CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings results on Thursday, August 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.15). CureVac had a return on equity of 29.57% and a net margin of 38.21%.The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $4.27 million. Analysts anticipate that CureVac will post 0.72 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
- 3 Stocks to Buy For the COVID Resurgence
CVAC has been the subject of a number of research analyst reports. Citizens Jmp lowered CureVac from a "strong-buy" rating to a "hold" rating in a report on Thursday, June 12th. UBS Group downgraded shares of CureVac from a "strong-buy" rating to a "neutral" rating and dropped their price target for the stock from $12.00 to $5.50 in a research note on Thursday, June 26th. Citigroup downgraded shares of CureVac to a "market perform" rating in a research note on Thursday, June 12th. JMP Securities reiterated a "market outperform" rating and issued a $10.00 price objective on shares of CureVac in a report on Wednesday, May 28th. Finally, Jefferies Financial Group reissued a "hold" rating and set a $5.00 target price (down previously from $7.00) on shares of CureVac in a research report on Friday, June 13th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $6.83.
Read Our Latest Analysis on CureVac
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CVAC. Alpine Associates Management Inc. bought a new stake in shares of CureVac during the 2nd quarter valued at $10,703,000. Qube Research & Technologies Ltd acquired a new position in shares of CureVac during the 2nd quarter worth $6,419,000. Water Island Capital LLC acquired a new position in shares of CureVac during the 2nd quarter worth $5,197,000. JPMorgan Chase & Co. acquired a new position in shares of CureVac during the 2nd quarter worth $1,705,000. Finally, GSA Capital Partners LLP acquired a new position in shares of CureVac during the 1st quarter worth $853,000. 17.26% of the stock is owned by institutional investors and hedge funds.
About CureVac
(Get Free Report)CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Recommended Stories
- Five stocks we like better than CureVac
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Archer's Flight Milestones & Defense Wins Excite Wall Street
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Upstart Stock Could Pop on a Short Squeeze Soon
- How to Profit From Growth Investing
- This Railroad Stock Is Chugging Along to a New All-Time High
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in CureVac Right Now?
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
